Methods: After i.v. administration of ∼300 MBq Florbetaben, 10 subjects with Alzheimer's disease (AD) and 10 age-matched healthy volunteers (HV) underwent 3D-PET. Concentrations of parent compound and metabolites were determined in plasma and used as input functions. VOI-based tissue–activity curves (TACs) from 25 brain regions were analyzed using two tissue compartments with one input function (OIF) or three tissue compartments with two input functions (TIF) over a time range of 90 (OIF) and 200 (TIF) minutes. Also the multilinear reference tissue method MRTM3 was applied. The kinetics of the metabolite(s) was described by one tissue compartment (“simplified” K1 fixed). Distribution volume ratio (DVR), binding potential with reference to the total tracer plasma concentration (BPP) and standardized uptake value ratio (SUVR) were used to characterize specific binding (reference: cerebellar cortex). Effect size in group comparison was determined by Cohen's d.